SDEF 35th Hawaii Dermatology Seminar

SDEF: High-Dose PDT May Offer "Cure" for Acne

WAILEA, HAWAII — Aggressively dosed red light photodynamic therapy effectively destroys sebaceous glands, resulting in prolonged inhibition of sebum output and lasting cure of moderate-to-severe acne, according to Dr. R. Rox Anderson said. [Read More]

SDEF: Leg Vein Treatment Requires Algorithmic Approach

Newer agents, approaches, and techniques have made sclerotherapy more effective with fewer complications than ever before, whereas the basic goal of this therapy remains the same as it was 100 years ago, according to Dr. Margaret Mann. [Read More]

Blog: Could Sublative Rejuvenation Revolutionize Laser Field?

Sublation appears to be the new "it" word in skin laser rejuvenation. Studies have found that a device utilizing sublative technology was safe and effective for skin tightening and treating acne scars, even in darker skinned patients. [Read More]

SDEF: When Culturing for MRSA, Go Beyond the Nose

WAILEA, HAWAII – If you think stuffing some mupirocin ointment up the nose of a methicillin-resistant Staphylococcus aureus carrier constitutes an adequate attempt at decolonization, think again. [Read More]

SDEF: Fractional Lasers a "Go To" Device for Scar Treatment

Partially or fully ablative lasers are safe and effective tools to treat many types of scars and keloids, Dr. Suzanne L. Kilmer reported. [Read More]

Blog: "Techno Pearls" for Saving Time, Money in the Office

Dr. Daniel M. Siegel is a man of many slides, 240 to be exact. You would probably imagine a room full of glazed over faces at the end of a 240 slide presentation, but, in fact, it was just the opposite. [Read More]

SDEF: FDA Approval Expected this Month for Ipilimumab

WAILEA, HAWAII – Expect a flood of patient inquiries regarding ipilimumab beginning in late March, when it is widely expected to receive Food and Drug Administration marketing approval as the first new drug for melanoma in 13 years. [Read More]

SDEF: Psoriasis Comorbidities Carry Implications for Disease Management

Studies show that severe psoriasis is associated with a 50% increased risk of mortality and up to 5 years of life lost, according to Dr. Joel M. Gelfand. [Read More]

SDEF: Weigh Costs Versus Benefits of "Meaningful Use"

Dermatologists should think long and hard about costs and potential benefits before attempting "meaningful use" under the Centers for Medicare and Medicaid Services' electronic health record incentive program, according to Dr. Daniel M. Siegel, president-elect of the American Academy of Dermatology. [Read More]

SDEF: Capecitabine May Protect Against Skin Cancers After Transplant

WAILEA, HAWAII – Oral capecitabine shows considerable early promise for the secondary prevention of nonmelanoma skin cancers in solid organ transplant recipients and other immunosuppressed individuals, according to Dr. Paul Nghiem. [Read More]

SDEF: Consider Potential Risks of Newly Approved Therapeutics

The limitations of the drug approval process in fully characterizing a new drug's safety profile are clearly illustrated in the dermatologic therapeutics arena and clinicians should keep these limitations in mind when prescribing and counseling patients about a relatively new therapeutic agent, according to Dr. Joel M. Gelfand. [Read More]

Blog: New Isotretinoin Drug May Address Safety Concerns

Isotretinoin has taken a beating over the last several years. From IBD to suicide, the acne drug has been at the forefront of lawsuits and clinical debate. [Read More]

SDEF: Preconceived Melanoma Pathogenesis Called Into Question

Clinical observation calls into question some of the preconceived notions about melanoma pathogenesis, according to Dr. James M. Grichnik. [Read More]

SDEF: Abtropfung, Hochsteigerung Theories of Nevus Evolution Questioned

Theories of how nevi develop have received little attention in the last 100 years, but that appears to be changing, according to Dr. Ashfaq A. Marghoob. [Read More]

SDEF: New Melanoma Treatments Show Improved Survival

During the past 30 years, only two drugs – dacarbazine and interleukin-2 – have been approved by the Food and Drug Administration for treating metastatic melanoma, and while these drugs help control the disease in a small percentage of patients, they do not appear to improve survival. [Read More]

Seminars In Cutaneous Medicine And Surgery

Seminars in Cutaneous Medicine and Surgery publishes topical reviews that address critical advances in the practice of medical and surgical dermatology. In-depth coverage of topics integral to the specialty, includes dermatologic surgery, general dermatology and dermatopathology.

2012 Topics:

March 2012 - Updates in Medical Dermatology

June 2012 - Frontiers in Dermatologic Surgery

September 2012 - eDermatology

December 2012 - Molecular Dermatology and Pathology

More Seminars »

This site complies with the HONcode standard for trustworthy health information: verify here.